Issue link: http://sarahcannon.uberflip.com/i/1492123
0208/23SCB003/R6 In 2022, Sarah Cannon Research Institute (SCRI) formed a joint venture with US Oncology Research (USOR) to enhance clinical trial access and availability across the country. *Presentations highlighted in blue represent research that was conducted across SCRI and the Sarah Cannon Transplant & Cellular Therapy Network, a Network of nine FACT/ JACIE accredited transplant centers across HCA Healthcare. TANDEM TRANSPLANTATION AND CELLULAR THERAPY MEETINGS 2023 PRESENTATION CALENDAR 2 THURSDAY, FEBRUARY 16 TH 5:45pm - 6:45pm Eastern Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title Author List *Legacy SCRI and Sarah Cannon Transplant & Cellular Therapy Network authors in blue, lead authors Bold *Legacy USOR authors in orange, lead authors Bold Session Name 5:45 - 6:45pm Poster 465 Development and Implementation of an Escalation Process to Address Psychosocial Support Needs Identified in the Pre- Transplant Phase Martin C, Meadors S, Malik S, Collins K, Velasquez T, Brooks KA, Scofield D, Clemmer K, Stentz J, Rana C, Burton MJ, Ramakrishnan A, Shaughnessy PJ Poster Session: Intersectionality, Diversity, and Inclusion & Removing Barriers to Access in TCT 5:45 - 6:45pm Poster 273 Outcomes for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network Battiwalla M, Tees M, Flinn IW, Pantin J, Gregory T, Maris M, Bhushan V, Vance E, Mathews J, Bachier C, Shaughnessy PJ, Ramakrishnan A, Malik S, Mori S, Gergis U, Billups R, Blunk B, LeMaistre CF, Majhail NS Poster Session: Engineered Immune Cells (CAR-T, NK, TCR): Clinical - Immune Effector Cells for Heme Malignancies 5:45 - 6:45pm Poster 231 Safety and Graft Characteristics of G-CSF Primed Bone Marrow in Donors with Sickle Cell Trait Evans M, Kelly S, Molinari L, Domm J, Carroll C, Greer L, Ward S, McManus M, Frangoul H Poster Session: Donor Safety, Unique Mobilizations, and Health Services 5:45 - 6:45pm Poster 458 Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships Banerjee R, Kelkar AH, Durani U, Anagnostou T, Nishitani M, Mallhi K, Majhail N, Logan AC Poster Session: Intersectionality, Diversity, and Inclusion & Removing Barriers to Access in TCT 5:45 - 6:45pm Poster 268 Outpatient CAR T Cell Therapy Is Safe and Feasible in Patients with Lymphoma Treated in Non-University Medical Centers: A Multicenter, Retrospective Analysis. Patel K, Bailey M, Bailey N, Fanning S, Gulley K, Frisvold J, Glennie S, Dunleavy V, Benitez-Kruidenier S, Parker J, Williams S, Sullivan S, Dean C, Hohmann H, Lu C, Tierney C, Mun G, Egan DN, Essell J Poster Session: Engineered Immune Cells (CAR-T, NK, TCR): Clinical - Immune Effector Cells for Heme Malignancies 5:45 - 6:45pm Poster 493 Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation (AHCT) for Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL): Secondary Analysis from Two Multicenter Randomized Controlled Trials (RCT) of Hematopoietic Cell Transplant Survivorship Interventions Mian A, Wei W, Chakraborty R, Yi J, Preussler JM, Bill BT, Cerny J, Deol A, Hahn TE, Hashmi SJ, Jaglowski S, Jim HS, Khera N, Loren AW, McGuirk JP, Savani B, Stiff P, Uberti J, Whalen V, Wingard JR, Reynolds J, Holtan SG, Wood WA, Baker S, Syrjala KL, Hamilton BK, Majhail NS Poster Session: Late Effects, Quality of Life, and Accelerated Aging 5:45 - 6:45pm Poster 184 A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus SOC in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E-CELERATE; NCT05181540): Trial in Progress Scordo M, Shouse G, Mountjoy L, Gauthier J, Mulroney C, Dholaria B, Rowley SD, Pantin J, DeFilipp Z, Mead M, Pawarode A, Qazilbash MH, Beitinjaneh A, Bubalo J, Khanal R, Abedi M, Finnegan P Poster Session: Acute Regimen-Related Toxicity and Supportive Care 5:45 - 6:45pm Poster 507 Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of Zuma-1 Cohort 6 Oluwole OO, Forcade E, Munoz J, de Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney PA, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Zheng Y, Vardhanabhuti S, Nater J, Shen RR, Miao H, Kim JJ, van Meerten T Poster Session: Lymphoma/CLL- Clinical

